



Day, E., Hellard, M., Treloar, C., Bruneau, J., Martin, N. K., Øvrehus, A., Dalgard, O., Lloyd, A., Dillon, J., Hickman, M., Byrne, J., Litwin, A., Maticic, M., Bruggmann, P., Midgard, H., Norton, B., Trooskin, S., Lazarus, J. V., Grebely, J., & the International Network on Hepatitis in Substance Users (INHSU) (2019). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. *Liver International*, 39(1), 20-30. <https://doi.org/10.1111/liv.13949>

Peer reviewed version

Link to published version (if available):  
[10.1111/liv.13949](https://doi.org/10.1111/liv.13949)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Wiley at <https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.13949> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>



**Hepatitis C elimination among people who inject drugs:  
Challenges and recommendations for action within a health  
systems framework**

Journal:	<i>Liver International</i>
Manuscript ID	LIVint-18-00873.R1
Wiley - Manuscript type:	Reviews
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Day, Emma; Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Viral Hepatitis and Substance Use          Hellard, Margaret; Burnet Institute, Disease Elimination Program          Treloar, Carla ; University of New South Wales Centre for Social Research in Health, Centre for Social Research in Health          Bruneau, Julie; Universite de Montreal Faculte de medecine, Département de médecine familiale et médecine d'urgence          Martin, Natasha K; University of California, Division of Global Public Health          Oevrehus, Anne; Odense Universitetshospital, Department of Infectious Diseases          Dalgard, Olav; Rikshospitalet, Department of Internal Medicine          Lloyd, Andrew; UNSW, School of Medical Sciences          Dillon, John ; University of Dundee, School of Medicine          Hickman, Matthew ; University of Bristol , Medical School          Litwin, Alain; University of South Carolina School of Medicine, School of Medicine          Byrne, Jude; Australian Injecting &amp; Illicit Drug Users League, Australian Injecting &amp; Illicit Drug Users League          Maticic, Mojca; University Medical Centre, Clinic for Infectious Diseases and Febrile Illnesses          Bruggmann, Philip; Arud Zentren fur Suchtmedizin, Arud          Midgard , Harvard; Oslo universitetssykehus Ulleval, Department of Gastroenterology          Norton , Brianna ; Montefiore Hospital and Medical Center, Division of General Internal Medicine          Trooskin, Stacey; University of Pennsylvania Perelman School of Medicine, Division of Infectious Diseases          Lazarus, Jeffrey; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona; CHIP, Righospitalet, WHO Collaborating Centre on HIV and Viral Hepatitis, University of Copenhagen.          Grebely, Jason; The Kirby Institute, UNSW Sydney</p>
Keywords:	Elimination, Health Systems, People who inject drugs, Viral Hepatitis C

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

SCHOLARONE™  
Manuscripts

For Peer Review

1  
2  
3 **Hepatitis C elimination among people who inject drugs: Challenges and recommendations for**  
4 **action within a health systems framework**  
5  
6  
7

8 Emma Day<sup>1</sup>, Margaret Hellard<sup>2</sup>, Carla Treloar<sup>3</sup>, Julie Bruneau<sup>4</sup>, Natasha K Martin<sup>5</sup>, Anne Øvrehus<sup>6</sup>,  
9 Olav Dalgard<sup>7</sup>, Andrew Lloyd<sup>8</sup>, John Dillon<sup>9</sup>, Matt Hickman<sup>10</sup>, Jude Byrne<sup>11</sup>, Alain Litwin<sup>12</sup>, Mojca  
10 Maticic<sup>13</sup>, Philip Bruggmann<sup>14</sup>, Havard Midgard<sup>15</sup>, Brianna Norton<sup>12</sup>, Stacey Trooskin<sup>16</sup>, Jeffrey V  
11 Lazarus<sup>17\*</sup>, and Jason Grebely<sup>8\*</sup> on behalf of the International Network on Hepatitis in Substance  
12 Users (INHSU) \*contributed equally  
13  
14  
15  
16  
17  
18

19  
20  
21 <sup>1</sup>Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine, Sydney, New South  
22 Wales, Australia; <sup>2</sup>Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia;  
23 <sup>3</sup>Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia; <sup>4</sup>CHUM  
24 Research Centre (CRCHUM), Centre Hospitalier de l'Université de Montréal, Montréal,  
25 Canada; <sup>5</sup>Division of Global Public Health, University of California, San Diego, California, United  
26 States; <sup>6</sup>Department of Infectious Diseases, Odense University Hospital, Denmark; <sup>7</sup>Department of  
27 Infectious Diseases, Akershus University Hospital, Institute of Clinical Medicine, University of Oslo,  
28 Oslo, Norway; <sup>8</sup>The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia; <sup>9</sup>Division  
29 of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, United  
30 Kingdom; <sup>10</sup>Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United  
31 Kingdom; <sup>11</sup>Australian Injecting & Illicit Drug Users League, Canberra, Australian Capital Territory,  
32 Australia; <sup>12</sup>Division of General Internal Medicine, Albert Einstein College of Medicine, Montefiore  
33 Medical Center, New York, United States;; <sup>13</sup>Clinic for Infectious Diseases and Febrile Illnesses,  
34 University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana,  
35 Slovenia; <sup>14</sup>Arud Centres for Addiction Medicine Zürich, Switzerland; <sup>15</sup>Department of  
36 Gastroenterology, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo,  
37 Norway; <sup>16</sup>Philadelphia FIGHT, Philadelphia, Pennsylvania, United States; <sup>17</sup>Barcelona Institute for  
38 Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Corresponding Author**

Emma Day

Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine

Level 7, 46 Kippax Street

Sydney

New South Wales, Australia

+61 2 8204 0769

[Emma.day@ashm.org.au](mailto:Emma.day@ashm.org.au)

**Word Count:** 3,500

**Number of figures and tables:** 2 Figures, No Tables

**Abbreviations**

DAA - direct-acting antiviral

PWID - people who inject drugs

WHO - World Health Organization

INHSU – International Network on Hepatitis in Substance Users

OST - opioid substitution therapy

NSP - needle and syringe programmes

DBS - dried blood spot

**Acknowledgments**

The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. NM is supported by the National Institute for Drug Abuse [grant number R01 DA037773] and the University of California San Diego Center for

1  
2  
3 AIDS Research (CFAR), a National Institute of Health (NIH) funded program [grant number  
4 P30 AI036214]. The authors wish to thank Tim France for preparing the original figure<sup>3</sup>  
5  
6 which has been adapted for Figure 2.  
7  
8  
9

### 10 **Declaration of interests**

11  
12 ED nothing to declare. JG is a consultant/advisor and has received research grants from  
13 AbbVie, Cepheid, Gilead Sciences and Merck/MSD outside of this work. JVL is a  
14  
15 consultant/advisor or has received research grants from AbbVie, Cepheid, Gilead Sciences  
16  
17 and Merck/MSD outside of this work. CT nothing to declare. NM has received unrestricted  
18  
19 research grants and honoraria from Gilead Sciences and Merck outside of this work. OD has  
20  
21 received research funding from Abbvie Gilead Sciences and MSD and is on advisory boards  
22  
23 for Abbvie and MSD outside of this work. JD has received grant/research support from  
24  
25 AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline,  
26  
27 Janssen, Merck Sharp & Dohme, Roche, Genedrive and speaker honoraria from AbbVie,  
28  
29 Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Janssen,  
30  
31 Merck Sharp & Dohme, Roche outside of this work. JB has nothing to declare. AL is a  
32  
33 consultant/advisor and has received research grants from Gilead Sciences and Merck/MSD  
34  
35 outside of this work. MM has nothing to declare. PB is a consultant/advisor and has received  
36  
37 research/travel grants from AbbVie, Gilead Sciences and Merck/MSD outside of this work.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 50 **Financial Support**

51 Nothing to report

## Abstract

The burden of hepatitis C infection is considerable among people who inject drugs (PWID), with an estimated prevalence of greater than 40%, representing an estimated 5.6 million people who have recently injected drugs living with hepatitis C infection. As such, PWID are a priority population for enhancing prevention, testing, linkage to care, treatment and follow-up care in order to meet World Health Organization (WHO) hepatitis C elimination goals by 2030. There are many barriers to enhancing hepatitis C prevention and care among PWID including: poor global coverage of harm reduction services, restrictive drug policies and criminalization of drug use, poor access to health services, low hepatitis C testing, linkage to care and treatment, restrictions for accessing DAA therapy, and the lack of national strategies and government investment to support WHO elimination goals. On 5 September 2017, the International Network of Hepatitis in Substance Users (INHSU) held a roundtable panel of international experts to discuss remaining challenges and future priorities for action from a health systems perspective. The WHO health systems framework comprises six core components; service delivery, health workforce, health information systems, medical procurement, health systems financing, and leadership and governance. Communication has been proposed as a seventh key element which promotes the central role of affected community engagement. This review paper presents recommended strategies for eliminating hepatitis C as a major public health threat among PWID and outlines future priorities for action within a health systems framework.

**Key words:** elimination; health systems; people who inject drugs; viral hepatitis C

### Key Points:

- PWID are a priority population in efforts to eliminate hepatitis C globally
- There are many interventions effective for hepatitis C prevention, linkage to testing, care, and treatment in PWID
- Future efforts to eliminate hepatitis C among PWID requires interventions across the six core components of a health systems framework including: service delivery, health workforce, health information systems, medical procurement, health systems financing, and leadership and governance
- Communication is a key component of the hepatitis C elimination response, promoting the central role of community engagement and ensuring dynamic interaction among the six traditional building blocks

## Introduction

Hepatitis B and hepatitis C account for approximately 1.34 million deaths globally, surpassing all chronic infectious diseases including HIV, malaria and tuberculosis<sup>4</sup>. It is estimated that 71 million people are living with chronic hepatitis C infection<sup>5</sup>. The burden of hepatitis C-related morbidity and mortality continues to rise<sup>4,6</sup>. However, broad access to direct-acting antiviral (DAA) hepatitis C regimens with cure rates of over 95%<sup>7</sup>, provides an opportunity to reverse the rising burden of liver disease attributable to hepatitis C infection.

The burden of hepatitis C infection is considerable among people who inject drugs (PWID), with an estimated prevalence of greater than 40%, representing an estimated 6.1 million people who have recently injected drugs living with hepatitis C infection (9% of all infections globally)<sup>5,8,9</sup>. There is also considerable heterogeneity in the burden of hepatitis C infection among people who have recently injected drugs (Figure 1), with half of infections from just four countries: the Russian Federation, the United States, China, and Brazil<sup>9</sup>. PWID are a priority population for enhancing prevention, testing, linkage to care, treatment and follow-up care.

In 2016, the World Health Organization (WHO) set an ambitious goal to eliminate hepatitis C as a major public health threat by 2030. Specific targets include increasing sterile needles/syringes distributed from 20 to 200 per person per year for PWID, reducing new hepatitis C infections by 80%, and hepatitis C -related deaths by 65%, and increasing hepatitis C diagnoses from <20% to 90%, and the number of people receiving hepatitis C treatment from <10% to 80%<sup>10,11</sup>.



1  
2  
3 There are many barriers to enhancing hepatitis C prevention, diagnosis, linkage to care and  
4 treatment to achieve the WHO targets among PWID. Challenges include poor global  
5 coverage of harm reduction services, restrictive drug policies and criminalization of drug use,  
6  
7 poor access to health services, low hepatitis C testing, linkage to care and treatment,  
8  
9 restrictions for accessing DAA therapy, and the lack of national strategies and government  
10  
11 investment to support WHO elimination goals<sup>7,12</sup>.  
12  
13  
14  
15  
16  
17

18 However, recent advances in the simplification of hepatitis C testing, diagnosis and treatment  
19 present an opportunity to enhance hepatitis C care among PWID. On 5 September 2017, prior  
20 to the 6<sup>th</sup> International Symposium on Hepatitis in Substance Users (INHSU 2017), the  
21 International Network of Hepatitis in Substance Users (INHSU) held a roundtable panel of  
22 international experts in drug and alcohol, infectious diseases, and hepatology to discuss  
23 remaining challenges and future priorities for action from a health systems perspective.  
24  
25 Concepts and priorities were further developed through subsequent consultation. This paper  
26 presents recommended actions based on the expert input from the roundtable, follow-up  
27 consultation and evidence from the literature. It highlights the available scientific evidence  
28 regarding strategies to enhance hepatitis C prevention, testing, linkage to care, and treatment  
29 for PWID and outlines future priorities for action within a health systems framework.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 ***Interventions to enhance hepatitis C prevention, testing and treatment to achieve hepatitis***  
45 ***C elimination among people who inject drugs***

46 ***Hepatitis C prevention***

47  
48  
49  
50 In 2015, there were an estimated 1.7 million new hepatitis C infections globally, with 23%  
51 occurring among people who inject drugs as a result of sharing of non-sterile injecting  
52  
53  
54  
55  
56  
57

1  
2  
3 equipment<sup>11</sup>, highlighting the elevated hepatitis C incidence among PWID in many settings<sup>13-</sup>  
4  
5 <sup>16</sup>, particularly in the initial years of injecting<sup>14,17</sup>.

6  
7  
8  
9  
10 There is evidence of the effectiveness of combined opioid substitution therapy (OST) and  
11  
12 high-coverage needle and syringe programmes (NSP) on reducing the risk of hepatitis C  
13  
14 acquisition in PWID<sup>14,15</sup>. OST is associated with a 50% reduction in hepatitis C acquisition  
15  
16 risk, while combined OST and NSP are associated with a 74% reduction in hepatitis C  
17  
18 transmissions<sup>18</sup>. NSP are also recognized as one of the most cost-effective public health  
19  
20 interventions<sup>19</sup>. NSP and OST also have many other social, health and economic benefits  
21  
22 beyond hepatitis C prevention, including prevention of HIV transmission and reducing death  
23  
24 from overdose<sup>20-22</sup>.

25  
26  
27  
28  
29 Increasing hepatitis C treatment among PWID also has potential prevention benefits and is  
30  
31 cost-effective<sup>23-25</sup>. As per international guidelines, given PWID are at a high risk of hepatitis  
32  
33 C transmission, and hepatitis C treatment resulting in cure eliminates infectiousness which  
34  
35 may yield transmission reduction benefits, PWID are a high priority for treatment<sup>26-29</sup>.

36  
37  
38  
39  
40 However, mathematical modelling studies suggest that whilst hepatitis C treatment for PWID  
41  
42 can lead to substantial reductions in hepatitis C prevalence and reduce transmission<sup>30-34</sup>,  
43  
44 prevention benefits are greatest when delivered in combination with OST and NSP<sup>31,35,36</sup>.  
45  
46 Similarly, theoretical modelling indicates that whilst harm reduction has likely averted high  
47  
48 HCV prevalence in some settings, scale-up of OST and NSP alone is unlikely to achieve  
49  
50 WHO elimination incidence targets<sup>31,37</sup>. Therefore, a combination prevention strategy  
51  
52 including hepatitis C treatment as prevention and increased coverage of harm reduction  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 interventions is critical for achieving reductions in hepatitis C prevalence/incidence among  
4  
5 PWID<sup>23</sup>.  
6  
7

### 8 9 *Hepatitis C testing*

10 Globally, hepatitis C testing and diagnosis remains inadequate, both in terms of numbers  
11 (<20% diagnosed) and completeness of tests offered (even fewer have been HCV RNA  
12 tested), in particular for PWID<sup>38-41</sup>. In a systematic review of the effectiveness of  
13 interventions to improve hepatitis C testing among PWID, on-site testing with pre-test  
14 discussion and education and dried blood spot (DBS) testing were demonstrated to be  
15 effective in increasing hepatitis C testing among PWID when compared to control  
16 interventions<sup>42</sup>. Other strategies that have been evaluated (without any comparator  
17 intervention) include physical and electronic medical chart reminders to prompt targeted risk-  
18 based assessment and testing<sup>43-47</sup>, peer-delivered outreach hepatitis C testing and hepatitis C  
19 education<sup>48</sup>, prison-based outreach testing<sup>49</sup>, patient referral contact tracing with monetary  
20 incentive for testing<sup>50</sup>, and point-of-care hepatitis C testing<sup>51-57</sup>. Decisions on what  
21 intervention(s) to implement to enhance hepatitis C testing will depend on the setting (and  
22 prevalence of hepatitis C infection), the model of care, the local context, and healthcare  
23 system. Decisions should also be based on engagement with the affected community to assess  
24 what testing interventions are most appropriate. Interventions should be implemented in a  
25 way that is respectful of individual choice and priorities. There is a lack of quality evidence  
26 on the most effective testing strategies, as such, strategies should be trialed and implemented  
27 in a way that is consultative and responsive rather than prescriptive.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 52 *Linkage to hepatitis C care and treatment*

1  
2  
3 Linkage of PWID to hepatitis C care and treatment is insufficient internationally<sup>38-40</sup>. In a  
4  
5 systematic review of studies to improve linkage to hepatitis C care for PWID in the  
6  
7 interferon-era, facilitated referral (either a nurse, peer-support worker or patient navigator)  
8  
9 for hepatitis C assessment and scheduling of specialist appointments was associated with  
10  
11 improved linkage to hepatitis C care<sup>42</sup>. Integrated hepatitis C care within drug use and  
12  
13 psychiatric services delivered by a multidisciplinary team with case management services,  
14  
15 with or without non-invasive liver disease assessment, was associated with improved  
16  
17 hepatitis C treatment uptake<sup>42</sup>. Other strategies evaluated and shown to enhance hepatitis C  
18  
19 linkage to care and treatment include dried blood spot testing<sup>58</sup>, point-of-care hepatitis C  
20  
21 testing<sup>54,55</sup>, non-invasive liver disease screening using transient elastography (FibroScan<sup>®</sup>)  
22  
23 with facilitated referral to care<sup>59-61</sup>, integrated hepatitis C care<sup>43,62-66</sup>, patient navigation  
24  
25 programs<sup>67,68</sup>, peer-based support<sup>69-81</sup>, financial incentive programs<sup>82,83</sup>, and telemedicine<sup>84-87</sup>.  
26  
27 However, the majority of interventions that have been evaluated are specific for the  
28  
29 interferon-era. Further research is needed to evaluate optimal interventions for linkage to  
30  
31 hepatitis C care and treatment with interferon-free DAA therapy. Similar to efforts to increase  
32  
33 hepatitis C testing, decisions on what intervention(s) to implement to enhance hepatitis C  
34  
35 linkage to care and treatment will depend on the setting and prevalence of hepatitis C  
36  
37 infection, the model of care, and the local context and healthcare system (which includes who  
38  
39 can prescribe therapy and the reimbursement restrictions in place).  
40  
41  
42  
43  
44  
45

#### 46 *Models of hepatitis C care*

47

48 There is evidence that different models of care are effective for linkage of PWID to hepatitis  
49  
50 C care and treatment including in hospital-based specialist clinics, community health centers,  
51  
52 drug treatment clinics, prisons, NSP, supervised consumption rooms, and primary care<sup>88</sup>. The  
53  
54 common theme from this spectrum of hepatitis C care models is that “one size does not fit  
55  
56  
57

1  
2  
3 all<sup>88</sup>. Models of care which provide on-site hepatitis C care in venues where PWID are  
4 already accessing services are important<sup>88</sup>. With the availability of simple DAA therapies, the  
5 expansion of hepatitis C care to primary care, prisons, and other non-hospital settings, as well  
6 as broadening the types of health care professionals providing care, will greatly enhance  
7 access to hepatitis C care and treatment for PWID.  
8  
9  
10  
11  
12  
13  
14  
15

### 16 *Hepatitis C treatment*

17 DAA therapy has improved the feasibility of hepatitis C treatment among PWID compared to  
18 interferon-based therapies, given DAA therapies have limited psychiatric side-effects, are  
19 simpler (oral, once-daily vs. weekly injections), and shorter in duration (8-12 weeks vs. 24-48  
20 weeks). DAA therapy is effective among PWID receiving OST<sup>89-99</sup>, people with a history of  
21 injecting drug use<sup>82,100-105</sup>, and recent PWID<sup>99,106-108</sup>, including those with hepatitis C/HIV co-  
22 infection<sup>93-95,101,104,105,109</sup>. There is no impact of drug use prior to or during treatment on  
23 response to DAA therapy among people receiving OST<sup>98,99</sup> or people with recent injecting  
24 drug use<sup>99,108</sup>. Concomitant alcohol use also has no impact on DAA treatment outcomes<sup>110</sup>.  
25 Hepatitis C reinfection incidence among PWID is 0.0-5.3/100 person-years<sup>111-118</sup>, with higher  
26 rates among those with ongoing injecting (4.9-6.4/100 person-year)<sup>112,114,115,117</sup>. Strategies to  
27 enhance hepatitis C prevention, such as access to high-coverage NSP and OST (>200 needle-  
28 syringes distributed per PWID and >40 OST recipients per 100 PWID) are crucial to  
29 minimize hepatitis C reinfection risk.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 ***Remaining challenges and key recommendations for action from a health systems*** 49 ***perspective to achieve hepatitis C elimination among people who inject drugs*** 50

#### 51 *Health Systems Building Blocks*

52  
53  
54  
55  
56  
57

1  
2  
3 A health system, as defined by WHO is all the organizations, institutions, resources and  
4  
5 people whose primary purpose is to improve health<sup>1,2</sup>. The WHO health systems framework  
6  
7 comprises six core components, some of which underpin other components, such as  
8  
9 leadership/governance and health information systems, others are input components to the  
10  
11 health system (financing and the health workforce), or reflect the outputs of the health system  
12  
13 (medical products and technologies and service delivery)<sup>1,2</sup>. Communication has been  
14  
15 proposed as a seventh key element. This promotes the central role of communication in the  
16  
17 context of affected community engagement and ensures dynamic interaction among the six  
18  
19 traditional building blocks<sup>1,2</sup>.

20  
21  
22  
23  
24 Given the interdependent nature of health system components, barriers to hepatitis C care and  
25  
26 treatment should be systematically addressed across all elements of the health systems  
27  
28 framework to support sustainable improvement throughout the care cascade (Figure 2).  
29  
30

### 31 32 33 *Communication and Engagement*

34  
35 A people-centered approach to the health systems framework promotes health care that is  
36  
37 respectful of, and responsive to, the preferences, needs and values of affected communities. If  
38  
39 communication and engagement is established as essential to the health systems framework  
40  
41 this component provides a central tenet on which health strategies can be structured. As  
42  
43 people who are actively involved in their own health care tend to have better outcomes<sup>119</sup>,  
44  
45 there is potential to move beyond inefficient and inequitable health systems by focusing on  
46  
47 patient participation and community-led health interventions.  
48  
49

50  
51  
52 Key actions to enhance hepatitis C care for PWID through communication and patient  
53  
54 engagement include:  
55  
56  
57

- 1) Enhancing health care worker communication through education on stigmatizing language/terminology, attitudes, practices and policies;
- 2) Providing peer-led hepatitis C, health promotion and health literacy education through drug user organisations;
- 3) Facilitating consumer participation in hepatitis service design and delivery;
- 4) Facilitating patient engagement in hepatitis C communication strategies;
- 5) Ensuring patient representation on national hepatitis C strategy planning committees/reference groups.

### *Service Delivery*

Service delivery is the provision of healthcare to people. All inputs to the health system, for example health workforce, medical procurement and health information systems are intended to enhance service delivery. WHO categorises good service delivery as possessing the following key characteristics: comprehensiveness, accessibility, coverage, continuity, quality, person-centeredness, coordination, and accountability and efficiency<sup>1</sup>.

As previously mentioned, there are many effective models of hepatitis C service delivery shown to successfully link PWID to care and treatment, all of which require contextual considerations such as individual diversity and culture. The same considerations need to be applied to pro-active testing outreach campaigns for those individuals not connected to any healthcare services.

New DAA therapies have simplified on-treatment monitoring and the resulting hepatitis C care pathway. This has increased the number of settings where hepatitis C services can be provided and has enabled a broader range of practitioners to be involved in prescribing (drug

1  
2  
3 and alcohol specialists, general practitioners, pharmacists, nurses, and physician assistants)  
4  
5 and supporting people through testing and care. This simplification has led to a wide  
6  
7 spectrum of models of care that can improve hepatitis C service delivery.  
8  
9

10  
11 Key actions to enhance hepatitis C service delivery include:  
12

- 13 1) Establishing and supporting hepatitis C testing methodologies that do not require  
14  
15 venepuncture (e.g. finger-stick and saliva) to enhance hepatitis C diagnosis, linkage to  
16  
17 care, and treatment in a variety of settings;
- 18 2) Supporting the concept of task-shifting towards the continued expansion of available  
19  
20 practitioners who can provide hepatitis C testing, linkage to care and treatment;  
21  
22  
23
- 24 3) Delivering services to PWID in a non-judgmental and non-stigmatizing way.  
25  
26  
27

### 28 *Health Workforce*

29  
30 The health workforce is defined as ‘all people engaged in actions whose primary intent is to  
31  
32 enhance health<sup>120</sup>. WHO identifies human resources as clinical staff, as well as management  
33  
34 and support staff, i.e. those who do not deliver services directly but are essential to the  
35  
36 performance of health systems<sup>1</sup>.  
37  
38  
39

40  
41 Given the ease and lower side-effect profile of DAA therapy, it is possible to increase  
42  
43 hepatitis C treatment through simplified models of care across a range of settings<sup>88</sup>.  
44

45  
46 Integrating hepatitis C care into new settings, for example drug and alcohol services, entails  
47  
48 service delivery by a broader multidisciplinary health workforce not previously involved in  
49  
50 hepatitis C management<sup>42</sup>.  
51  
52  
53  
54  
55  
56  
57



1  
2  
3 Key actions to enhance hepatitis C care for PWID through strengthening the health workforce  
4  
5 include:

- 6  
7 1) Addressing health workforce limitations through increased hepatitis C education.  
8  
9 Education must be contextually and culturally appropriate and provided through  
10  
11 flexible, blended learning i.e. online and face-face. Education should focus on  
12  
13 capacity strengthening within health systems through ‘train the trainer’ models and  
14  
15 include a key focus on providing non-stigmatizing care;  
16  
17  
18 2) Developing and expanding the peer workforce. Peer-based models of care receive a  
19  
20 high level of patient acceptability and are an effective way of creating trust between  
21  
22 services, healthcare providers and patients<sup>69,121</sup>. Health practitioner definitions should  
23  
24 be expanded to include peer workers as valued members of the health workforce and  
25  
26 peers should be supported through appropriate remuneration and professional  
27  
28 support/supervision;  
29  
30  
31 3) Encouraging and driving leadership within the workforce e.g. by reaching out to  
32  
33 professional groups to create champions in various relevant disciplines.  
34  
35  
36

### 37 *Health Information Systems*

38  
39 Health information systems are the foundation of decision-making across the health system.  
40  
41 They enable decision-makers to identify problems and needs, make evidence-based decisions  
42  
43 on health policy, and allocate resources optimally<sup>122</sup>.  
44  
45  
46  
47

48  
49 Despite epidemiological estimates relating to hepatitis C prevalence and burden of disease  
50  
51 within PWID, there are still gaps in research and monitoring data. Addressing evidence gaps  
52  
53 and improving methods for data collection is a priority for meeting global hepatitis C  
54  
55 elimination goals<sup>12</sup>.  
56  
57

1  
2  
3  
4  
5 Key actions to enhance hepatitis C care for PWID through health information systems

6  
7 include:

- 8  
9 1) Developing systems to enable electronic health medical record alerts to enhance  
10 hepatitis C testing in people at-risk who have not previously been tested or require  
11 ongoing risk-based testing;  
12  
13 2) Assisting clients to understand how their data will be used and how their privacy will  
14 be protected;  
15  
16 3) Collecting minimum program information at the outset of hepatitis C treatment scale-  
17 up that can monitor the uptake of hepatitis C case-finding among PWID, including the  
18 number and proportion that enter hepatitis C treatment programs;  
19  
20 4) Creating a hepatitis C treatment registry with linkage between laboratories and  
21 community hepatitis C treatment providers;  
22  
23 5) Developing more efficient/flexible digital means of capturing data on hepatitis C  
24 testing and treatment among PWID (particularly in settings where no registry exists or  
25 can be established);  
26  
27 6) Evaluating the impact of DAA treatment on hepatitis C-related morbidity and  
28 mortality, including hepatitis C prevalence and incidence, incidence of liver cancer  
29 and advanced liver disease (e.g. decompensated cirrhosis), and death among PWID.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 It is noted that as less restrictive care pathways are enabled through point-of-care testing and  
47 treatment access in community settings, it may become more challenging to establish or  
48 maintain classical disease registries. This reinforces the need to create alternative, digital  
49 means of capturing data.  
50  
51  
52  
53  
54  
55  
56  
57

### *Medical Procurement*

According to WHO, a well-functioning health system ensures equitable access to essential medical products and technologies of assured quality, safety, efficacy and cost-effectiveness<sup>123</sup>.

The availability of new hepatitis C diagnostics that are highly sensitive, quick and inexpensive, has facilitated the simplification of hepatitis C testing<sup>124-129</sup>. DAA therapies have also dramatically simplified on-treatment monitoring needs<sup>124</sup>.

Point-of-care and DBS testing have been shown to increase uptake of hepatitis C testing<sup>42,47,54-56,130</sup> and linkage to hepatitis C care<sup>54,55,58</sup>. Both have the potential to reduce non-attendance to off-site phlebotomy and provide more immediate results to facilitate enhanced education and linkage to care. This is particularly useful for remote/rural and outreach settings.

Point-of-care hepatitis C testing can include oral fluid rapid diagnostic testing<sup>125-129</sup>, finger-stick whole-blood rapid diagnostic testing<sup>126-129,131,132</sup>, on-site venepuncture-based testing<sup>133,134</sup>, and finger-stick capillary whole blood testing<sup>57</sup>. Although DBS testing is not strictly point-of-care, the ability to collect a finger-stick sample at the point-of-care simplifies sample collection, transportation to the laboratory, and diagnosis<sup>130,135-137</sup>.

Key actions to enhance hepatitis C care for PWID through medical procurement include:

- 1) Simplifying, and disinvesting from, existing clinical algorithms for testing and treatment, ensuring a focus on improvement engagement with PWID;

- 2) Increasing certification of currently available diagnostics – particularly those that do not require a venous blood draw - e.g. oral tests, finger-stick blood tests – to increase access to testing for PWID;
- 3) Developing and certifying affordable diagnostics – particularly those that focus on community-based testing and reduce phlebotomy – to increase access to testing for PWID.

### *Health Systems Financing*

Health financing is fundamental to the functionality of the health system. It involves both revenue generation/collection and purchasing/provision of services. Optimal health care financing allows access to needed services through efficient resource utilization.

The high cost of hepatitis C treatment continues to be a topic of concern; however, given economic and population prevention benefits, scaling up hepatitis C treatment and care in PWID has been shown to be cost-effective despite high drug costs and risk of reinfection<sup>23-25</sup>.

Globally, there is a lack of transparency in hepatitis c treatment financing mechanisms. Greater clarity and sharing of funding mechanisms would allow for a greater coordinated and effective global response.

Exploring new funding mechanisms and ensuring the financial sustainability of hepatitis C prevention and treatment programs should be an important focus for all health systems.

Key actions for enhancing hepatitis C care through financing include:

- 1) Identifying models of hepatitis C elimination success in settings with different economic health system structures and epidemic characteristics;

- 2) Advocating for transparent sharing of successes in drug procurement and pricing;
- 3) Developing investment cases including budgetary impact, epidemic impact (general and among PWID), cost-effectiveness and optimal resource allocation strategies ensuring equity.

### *Leadership and Governance*

Effective health system leadership and governance enables strategic policy frameworks, effective service delivery oversight, coalition-building, regulation, attention to system design and accountability<sup>123</sup>. As a cross-cutting component of the health systems framework, leadership and governance is an integral part of improving health outcomes.

In the context of eliminating hepatitis C, although “early adopter” countries, and regions / sites within countries, many of whom have developed national strategies, action plans and clinical guidelines, are showing that rapid scale up of testing and treatment can be achieved through committed political leadership<sup>11</sup>, not all areas have such governance guidelines. To meet elimination targets by 2030 a comprehensive and global public health approach is needed.

Key actions for enhancing hepatitis C prevention and care through leadership and governance include:

- 1) Encouraging all countries to develop a national strategy with an action plan;
- 2) Ensuring engagement of key affected populations, preferably through leadership roles, in the development of national strategies and action plans;
- 3) Developing treatment guidelines specifically noting that PWID should not be excluded from treatment and addressing primary prevention to prevent reinfection;

- 4) Ensuring a financial commitment from national and regional/state governments;
- 5) Identifying what scale-up of harm reduction interventions are required to support hepatitis C treatment as prevention strategy;
- 6) Developing mechanisms for monitoring and evaluation to be able to provide data on whether progress is being made;
- 7) Identifying champions to drive change – from the community, clinicians, public health and government.

## Conclusion

People who inject drugs, one of the populations most affected by hepatitis C, should be a priority population for interventions to prevent and treat the infection. If hepatitis C elimination is to be achieved a people-centered health systems approach is required, providing a framework for action in which PWID are engaged in all components of their care, from diagnosis to treatment and follow-up care. At present, this is seldom the case. This paper presents a series of recommendations, based on expert opinion and published evidence, for how to improve care for PWID in each of the WHO six health systems buildings blocks. The seventh central component - ensuring adequate communication among the different parts of the health system and the PWID population - is put forth as a core element of the hepatitis C elimination response.

## REFERENCES

1. WHO. *Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies*. Geneva, Switzerland.2010.
2. WHO. *Everybody business : strengthening health systems to improve health outcomes : WHO's framework for action*. Geneva, Switzerland2007.

3. Lazarus JV, France T. A new era for the WHO health system building blocks? 2014; <http://www.healthsystemsglobal.org/blog/9/A-new-era-for-the-WHO-health-system-building-blocks-.html>. Accessed June 30, 2018, 2018.
4. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet*. 2016;388(10049):1081-1088.
5. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastro Hepatol*. 2017;2(3):161-176.
6. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. *Nature Reviews in Gastroenterology & Hepatology*. 2013;10(9):553-562.
7. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. *Annals of internal medicine*. 2017;166(9):637-648.
8. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Global Health*. 2017;5(12):e1192-e1207.
9. Grebely J, Larney S, Peacock A, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. *Addiction*. 2018.
10. WHO. Global health sector strategy on viral hepatitis 2016-2021. 2017; <http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1>. Accessed June 5, 2017.
11. WHO. *Global Hepatitis Report 2017*. . Geneva: World Health Organization;2017.
12. Grebely J, Bruneau J, Lazarus JV, et al. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. *The International journal on drug policy*. 2017;47:51-60.
13. Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. *PloS one*. 2014;9(7):e103345.
14. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. *American journal of epidemiology*. 2008;168(10):1099-1109.
15. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2013;57 Suppl 2:S32-38.
16. Morris MD, Shiboski S, Bruneau J, et al. Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2017;64(7):860-869.
17. Roy E, Boudreau JF, Boivin JF. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. *Drug Alcohol Depend*. 2009;102(1-3):158-161.

18. Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. *Addiction*. 2017.
19. Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. *The International journal on drug policy*. 2015;26 Suppl 1:S5-11.
20. Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. *Addiction*. 2008;103(9):1484-1492.
21. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. *The Cochrane database of systematic reviews*. 2011(8):CD004145.
22. MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. *The International journal on drug policy*. 2014;25(1):34-52.
23. Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. *Lancet*. 2014;384(9958):1953-1997.
24. Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. *Hepatology*. 2012;55(1):49-57.
25. Martin NK, Vickerman P, Dore GJ, et al. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. *Journal of hepatology*. 2016;65(1):17-25.
26. AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 2017; <https://www.hcvguidelines.org/>. Accessed March 18, 2017.
27. EASL. EASL Recommendations on Treatment of Hepatitis C 2016. *Journal of hepatology*. 2017;66(1):153-194.
28. Grebely J, Robaey G, Bruggmann P, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *The International journal on drug policy*. 2015;26(10):1028-1038.
29. WHO. *Guidelines for the screening, care and treatment of persons with hepatitis C infection*. Geneva, Switzerland 2014.
30. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. *Journal of hepatology*. 2011;54(6):1137-1144.
31. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2013;57 Suppl 2:S39-45.
32. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology*. 2013;58(5):1598-1609.
33. de Vos AS, Prins M, Kretzschmar ME. Hepatitis C Virus treatment as prevention among injecting drug users: who should we cure first? *Addiction*. 2015.



- 1  
2  
3 34. Hellard M, Rolls DA, Sacks-Davis R, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. *Hepatology*. 2014;60(6):1861-1870.
- 4  
5  
6 35. Fraser H, Zibbell J, Hoerger T, et al. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. *Addiction*. 2018;113(1):173-182.
- 7  
8  
9 36. Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. *Journal of hepatology*. 2018;68(3):402-411.
- 10  
11  
12 37. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. *Addiction*. 2012;107(11):1984-1995.
- 13  
14  
15 38. Saraswat V, Norris S, de Knegt RJ, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. *Journal of viral hepatitis*. 2015;22 Suppl 1:6-25.
- 16  
17  
18 39. Liakina V, Hamid S, Tanaka J, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3. *Journal of viral hepatitis*. 2015;22 Suppl 4:4-20.
- 19  
20  
21 40. Bruggmann P, Berg T, Ovrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. *Journal of viral hepatitis*. 2014;21 Suppl 1:5-33.
- 22  
23  
24 41. Lazarus JV, Sperle I, Spina A, Rockstroh JK. Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe. *Croatian medical journal*. 2016;57(5):442-456.
- 25  
26  
27 42. Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. *The International journal on drug policy*. In Press.
- 28  
29  
30 43. Zhou K, Fitzpatrick T, Walsh N, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. *The Lancet Infectious diseases*. 2016.
- 31  
32  
33 44. Krauskopf K, Kil N, Sofianou A, et al. Evaluation of an electronic health record prompt for hepatitis c antibody screening of baby boomers in primary care-a cluster randomized control trial. *Journal of General Internal Medicine*. 2014;29:S88-S89.
- 34  
35  
36 45. Litwin AH, Smith BD, Drainoni ML, et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*. 2012;44(6):497-503.
- 37  
38  
39 46. Drainoni ML, Litwin AH, Smith BD, et al. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. *American journal of public health*. 2012;102(11):e115-121.
- 40  
41  
42 47. Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. *The International journal on drug policy*. 2015;26(10):922-935.
- 43  
44  
45 48. Aitken CK, Kerger M, Crofts N. Peer-delivered hepatitis C testing and counselling: a means of improving the health of injecting drug users. *Drug and alcohol review*. 2002;21(1):33-37.
- 46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
49. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: Implications for the national strategy. *Gut*. 2003;52(10):1500-1504.
50. Brewer DD, Hagan H. Evaluation of a patient referral contact tracing programme for hepatitis B and C virus infection in drug injectors. *Eurosurveillance*. 2009;14(14).
51. Conway B, Vafadary S, Sharma S, et al. The community pop-up clinic as a tool of engagement for vulnerable populations with HCV and HIV infections. *Journal of Hepatitis*. 2015;2(1):1-4.
52. Cosmaro ML, Oldrini M, Rancilio L, et al. Facilitated access procedures for HIV and HCV testing in vulnerable groups. *Infection*. 2011;39:S33.
53. Remy AJ, Bouchkira H, Wenger H, Montabone S. News tools of screening viral hepatitis in real life: New french model of care. *United European Gastroenterology Journal*. 2015;1):A157.
54. Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. *Journal of community health*. 2014;39(5):922-934.
55. Bottero J, Boyd A, Gozlan J, et al. Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. *Open forum infectious diseases*. 2015;2(4):ofv162.
56. Beckwith CG, Kurth AE, Bazerman LB, et al. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. *Journal of public health*. 2016;38(1):130-137.
57. Grebely J, Lamoury FMJ, Hajarizadeh B, et al. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. *Lancet Gastroenterol Hepatol*. 2017;2(7):514-520.
58. McAllister G, Innes H, McLeod A, et al. Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2014;61(3):359-364.
59. Moessner BK, Jorgensen TR, Skamling M, et al. Outreach screening of drug users for cirrhosis with transient elastography. *Addiction*. 2011;106(5):970-976.
60. Foucher J, Reiller B, Jullien V, et al. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. *Journal of viral hepatitis*. 2009;16(2):121-131.
61. Marshall AD, Micallef M, Erratt A, et al. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. *The International journal on drug policy*. 2015;26(10):984-991.
62. Cullen W, Stanley J, Langton D, Kelly Y, Staines A, Bury G. Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation. *The British journal of general practice : the journal of the Royal College of General Practitioners*. 2006;56(532):848-856.
63. Masson CL, Delucchi KL, McKnight C, et al. A Randomized Trial of a Hepatitis Care Coordination Model in Methadone Maintenance Treatment. *American journal of public health*. 2013;103(10):E81-E88.

- 1  
2  
3 64. Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated  
4 care intervention to increase eligibility for chronic hepatitis C treatment. *The*  
5 *American journal of gastroenterology*. 2011;106(10):1777-1786.  
6  
7 65. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a  
8 chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. *The*  
9 *American journal of gastroenterology*. 2006;101(10):2254-2262.  
10  
11 66. Ho SB, Brau N, Cheung R, et al. Integrated Care Increases Treatment and Improves  
12 Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness  
13 or Substance Abuse. *Clinical gastroenterology and hepatology : the official clinical*  
14 *practice journal of the American Gastroenterological Association*. 2015;13(11):2005-  
15 2014 e2001-2003.  
16  
17 67. Trooskin SB, Poceta J, Towey CM, et al. Results from a Geographically Focused,  
18 Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. *J*  
19 *Gen Intern Med*. 2015;30(7):950-957.  
20  
21 68. Falade-Nwulia O, Mehta SH, Lasola J, et al. Public health clinic-based hepatitis C  
22 testing and linkage to care in baltimore. *Journal of viral hepatitis*. 2016;23(5):366-  
23 374.  
24  
25 69. Crawford S, Bath N. Peer support models for people with a history of injecting drug  
26 use undertaking assessment and treatment for hepatitis C virus infection. *Clinical*  
27 *infectious diseases : an official publication of the Infectious Diseases Society of*  
28 *America*. 2013;57 Suppl 2:S75-79.  
29  
30 70. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for  
31 hepatitis C virus infection in illicit drug users: a novel model incorporating  
32 multidisciplinary care and peer support. *European journal of gastroenterology &*  
33 *hepatology*. 2010;22(3):270-277.  
34  
35 71. Norman J, Walsh NM, Mugavin J, et al. The acceptability and feasibility of peer  
36 worker support role in community based HCV treatment for injecting drug users.  
37 *Harm Reduct J*. 2008;5:8.  
38  
39 72. Rance J, Treloar C. *Integrating Treatment: Key findings from a qualitative evaluation*  
40 *of the Enhancing Treatment of Hepatitis C in Opiate Substitution Settings (ETHOS)*  
41 *study*. Sydney: National Centre in HIV Social Research;2012.  
42  
43 73. Musgrove SM. NUAA's ETHOS Projects: The Story of a Hep C Peer Support Worker &  
44 His Clinic. Paper presented at: 2nd International Symposium on Hepatitis in  
45 Substance Users2011; Brussels, Belgium.  
46  
47 74. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve  
48 engagement and outcomes. *The International journal on drug policy*. 2007;18(5):406-  
49 410.  
50  
51 75. Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent  
52 group treatment for hepatitis C: implementation and outcomes in a methadone  
53 maintenance treatment program. *Journal of substance abuse treatment*.  
54 2012;43(4):424-432.  
55  
56 76. Charlebois A, Lee L, Cooper E, Mason K, Powis J. Factors associated with HCV  
57 antiviral treatment uptake among participants of a community-based HCV  
58 programme for marginalized patients. *J Viral Hepat*. 2012;19(12):836-842.  
59  
60 77. Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. "It's easier to do  
stuff that's hard when you've got people to back you up:" description of a Hepatitis C

- Peer Education & Support Program in an opioid treatment program *TBD*. 2013;In Press.
78. Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. *Journal of health care for the poor and underserved*. 2014;25(2):652-662.
79. Treloar C, Rance J, Bath N, et al. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. *Int J Drug Policy*. 2015(In Press).
80. Alavi M, Grebely J, Micallef M, et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opiate substitution setting: the ETHOS study. *Clin Infect Dis*. 2013;In Press.
81. Keats J, Micallef M, Grebely J, et al. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. *The International journal on drug policy*. 2015;26(10):999-1006.
82. Sulkowski M, Ward K, Falade-Nwulia O, et al. Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfecting persons who inject drugs: the CHAMPS Study. *Journal of hepatology*. 2017;66:S719.
83. Norton BL, Singh R, Agyemang L, Litwin AH. Contingency Management Improves HCV Linkage and Treatment Outcomes in Persons Who Inject Drugs: A Pilot Study. Paper presented at: 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016)2016; Oslo, Norway.
84. Mashru J, Kirlew M, Saginur R, Schreiber YS. Management of infectious diseases in remote northwestern Ontario with telemedicine videoconference consultations. *Journal of telemedicine and telecare*. 2017;23(1):83-87.
85. Tahan V, Almashrawi A, Kahveci AM, Mutrux R, Ibdah JA. Extension for Community Health Outcomes-hepatitis C: Small steps carve big footprints in the allocation of scarce resources for hepatitis C virus treatment to remote developing areas. *World journal of hepatology*. 2016;8(11):509-512.
86. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. *The New England journal of medicine*. 2011;364(23):2199-2207.
87. Lloyd AR, Clegg J, Lange J, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2013;56(8):1078-1084.
88. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2013;57 Suppl 2:S56-61.
89. Grebely J, Puoti M, Wedemeyer H, et al. Safety and Efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Chronic Hepatitis C Patients Receiving Opioid Substitution Therapy: A Pooled Analysis Across 12 Clinical Trials. *Journal of hepatology*. 2017;66:S514.

- 1  
2  
3 90. Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and Safety of Sofosbuvir/Velpatasvir in  
4 Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution  
5 Therapy: Analysis of Phase 3 ASTRAL Trials. *Clinical infectious diseases : an official  
6 publication of the Infectious Diseases Society of America*. 2016.  
7  
8 91. Grebely J, Mauss S, Brown A, et al. Efficacy and Safety of Ledipasvir/Sofosbuvir With  
9 and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving  
10 Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. *Clinical infectious  
11 diseases : an official publication of the Infectious Diseases Society of America*. 2016.  
12 92. Grebely J, Jacobson IM, Kayali Z, et al. SOF/VEL/VOX for 8 or 12 Weeks Is Well  
13 Tolerated and Results in High SVR12 Rates in Patients Receiving Opioid Substitution  
14 Therapy. *Journal of hepatology*. 2017;66:S513.  
15 93. Christensen S, Schober A, Mauss S, et al. DAA-Treatment of HCV-infected patients on  
16 Opioid Substitution Therapy (OST): does the clinical setting matter? Data from the  
17 German Hepatitis C-Registry (DHC-R). *Hepatology*. 2016;64(S1):982A-983A.  
18 94. Schutz A, Moser S, Marchart K, Haltmayer H, Gschwantler M. Direct Observed  
19 Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-  
20 Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With  
21 Borderline Compliance Receiving Opioid Substitution Therapy. *The American journal  
22 of gastroenterology*. 2016;111(6):903-905.  
23 95. Scherz N, Brunner N, Bruggmann P. Direct-acting antivirals for hepatitis C in patient  
24 in opioid substitution treatment and heroin assisted treatment: real-life data. *Journal  
25 of hepatology*. 2017;66:S726.  
26 96. Dillon J, Mauss S, Nalpas C, et al. Efficacy and safety of Simeprevir-containing  
27 hepatitis C therapy in patients on opiate substitution therapy. *Journal of hepatology*.  
28 2017;66:S520.  
29 97. Boyle A, Marra F, Fox R, et al. Partial directly observed therapy with  
30 ombitasvir/paritaprevir based regimens allows for successful treatment of patients  
31 on daily supervised methadone. *Journal of hepatology*. 2017;66.  
32 98. Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus  
33 Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. *Annals of  
34 internal medicine*. 2016;165(9):625-634.  
35 99. Conway B, Grebely J, Fraser C, et al. Paritaprevir/ritonavir/ombitasvir, dasabuvir +  
36 ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving  
37 OST: The D3FEAT study. Paper presented at: 6th international Symposium on  
38 Hepatitis Care in Substance Users 2017; New Jersey, United States.  
39 100. Norton BL, Fleming J, Steinman M, et al. High HCV Cure Rates for Drug Users Treated  
40 with DAAs at an Urban Primary Care Clinic. Paper presented at: Conference on  
41 Retroviruses and Opportunistic Infections; Feb 22-24 2016; Boston, United States.  
42 101. Conway B, Raycraft T, Bhutani Y, et al. Efficacy of All-Oral HCV Therapy in People  
43 Who Inject Drugs. *Hepatology*. 2016;64(S1):990A.  
44 102. Morris L, Smirnov A, Kvassay A, et al. Initial outcomes of integrated community-  
45 based hepatitis C treatment for people who inject drugs: findings from the  
46 Queensland Injectors' Health Network. *The International journal on drug policy*.  
47 2017;In Press.  
48 103. Mason K, Dodd Z, Guyton M, et al. Understanding Real-World Adherence in the  
49 Directly Acting Antiviral Era: a prospective evaluation of adherence amongst people  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- with a history of drug use at a community-based program in Toronto, Canada. *The International journal on drug policy*. 2017;In Press.
104. Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. *The International journal on drug policy*. 2017;In Press.
105. Litwin AH, Agyemang L, Akiyama M, et al. The PREVAIL Study: Intensive Models of HCV Care for People Who Inject Drugs *Journal of hepatology*. 2017;66:S72.
106. Bouscaillou J, Kikvidze T, Butsashvili M, et al. Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia. *Journal of hepatology*. 2017;66:S409.
107. Boglione L, Mornese Pinna S, De Nicolo A, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. *Journal of viral hepatitis*. 2017.
108. Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. *Lancet Gastro Hepatol*. 2018;In Press.
109. Dore GJ, Altice F, Litwin AH, et al. Elbasvir/Grazoprevir to Treat HCV Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Controlled Trial (C-EDGE CO-STAR). *Annals of internal medicine*. 2016;In Press.
110. Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. *Drug and alcohol dependence*. 2016;169:101-109.
111. Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs--impact on therapy. *Nature reviews Gastroenterology & hepatology*. 2015;12(4):218-230.
112. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2013;57 Suppl 2:S80-89.
113. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2016;62(6):683-694.
114. Midgard H, Bjoro B, Maeland A, et al. Hepatitis C reinfection after sustained virological response. *Journal of hepatology*. 2016;64(5):1020-1026.
115. Weir A, McLeod A, Innes H, et al. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. *Drug and alcohol dependence*. 2016;165:53-60.
116. Pineda JA, Nunez-Torres R, Tellez F, et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. *The Journal of infection*. 2015;71(5):571-577.
117. Young J, Rossi C, Gill J, et al. Risk factors for hepatitis C virus reinfection after sustained virologic response in patients co-infected with HIV. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2017.


- 1  
2  
3 118. Dore GJ, Grebely J, Altice F, et al. HCV reinfection and injecting risk behavior  
4 following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-  
5 STAR Three Year Follow-up Study. *Hepatology*. 2016;64(S1):431A.  
6  
7 119. Rifkin SB. Examining the links between community participation and health  
8 outcomes: a review of the literature. *Health Policy Plan*. 2014;29 Suppl 2:ii98-106.  
9  
10 120. WHO. *The world health report 2006: working together for health*. 2018.  
11  
12 121. Treloar C, Rance J, Bath N, et al. Evaluation of two community-controlled peer  
13 support services for assessment and treatment of hepatitis C virus infection in opioid  
14 substitution treatment clinics: The ETHOS study, Australia. *The International journal*  
15 *on drug policy*. 2015;26(10):992-998.  
16  
17 122. WHO. *Health Metrics Network. Framework and standards for country health*  
18 *information systems*. . 2008.  
19  
20 123. WHO. *The world health report 2006 – working together for health*. Geneva,  
21 Switzerland.2006.  
22  
23 124. Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point-of-care diagnostics:  
24 in search of a single visit diagnosis. *Expert Rev Mol Diagn*. 2017;17(12):1109-1115.  
25  
26 125. Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of  
27 rapid hepatitis C screening with an oral swab for community-based organizations  
28 serving high-risk populations. *Am J Public Health*. 2011;101(11):2151-2155.  
29  
30 126. Jewett A, Smith BD, Garfein RS, Cuevas-Mota J, Teshale EH, Weinbaum CM. Field-  
31 based performance of three pre-market rapid hepatitis C virus antibody assays in  
32 STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San  
33 Diego, CA. *J Clin Virol*. 2012;54(3):213-217.  
34  
35 127. Smith BD, Teshale E, Jewett A, et al. Performance of premarket rapid hepatitis C virus  
36 antibody assays in 4 national human immunodeficiency virus behavioral surveillance  
37 system sites. *Clin Infect Dis*. 2011;53(8):780-786.  
38  
39 128. Smith BD, Drobeniuc J, Jewett A, et al. Evaluation of three rapid screening assays for  
40 detection of antibodies to hepatitis C virus. *J Infect Dis*. 2011;204(6):825-831.  
41  
42 129. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-  
43 care screening tests for hepatitis C: a systematic review and meta-analysis. *Annals of*  
44 *internal medicine*. 2012;157(8):558-566.  
45  
46 130. Coats JT, Dillon JF. The effect of introducing point-of-care or dried blood spot  
47 analysis on the uptake of hepatitis C virus testing in high-risk populations: A  
48 systematic review of the literature. *The International journal on drug policy*.  
49 2015;26(11):1050-1055.  
50  
51 131. Wong VW, Wong GL, Chim AM, et al. Targeted hepatitis C screening among ex-  
52 injection drug users in the community. *J Gastroenterol Hepatol*. 2013.  
53  
54 132. Poiteau L, Soulier A, Rosa I, et al. Performance of rapid diagnostic tests for the  
55 detection of antibodies to hepatitis C virus in whole blood collected on dried blood  
56 spots. *Journal of viral hepatitis*. 2016;23(5):399-401.  
57  
58 133. McHugh MP, Wu AHB, Chevaliez S, Pawlotsky JM, Hallin M, Templeton KE.  
59 Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay. *J Clin*  
60 *Microbiol*. 2017;55(5):1550-1556.  
134. Gupta E, Agarwala P, Kumar G, Maiwall R, Sarin SK. Point -of -care testing (POCT) in  
molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in  
diagnosing and monitoring of HCV infection. *Journal of clinical virology : the official*  
*publication of the Pan American Society for Clinical Virology*. 2017;88:46-51.

- 1  
2  
3 135. Chevaliez S, Poiteau L, Rosa I, et al. Prospective assessment of rapid diagnostic tests  
4 for the detection of antibodies to hepatitis C virus, a tool for improving access to  
5 care. *Clin Microbiol Infect.* 2016;22(5):459 e451-456.  
6  
7 136. Soulier A, Poiteau L, Rosa I, et al. Dried Blood Spots: A Tool to Ensure Broad Access to  
8 Hepatitis C Screening, Diagnosis, and Treatment Monitoring. *The Journal of infectious*  
9 *diseases.* 2016;213(7):1087-1095.  
10  
11 137. Greenman J, Roberts T, Cohn J, Messac L. Dried blood spot in the genotyping,  
12 quantification and storage of HCV RNA: a systematic literature review. *Journal of*  
13 *viral hepatitis.* 2015;22(4):353-361.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1. Estimated number of people with recent injecting drug use living with HCV viraemic infection, by country. This figure has been reproduced with permission from<sup>9</sup>.**



view

Figure 2. Proposed modified WHO Health Systems Framework for PWID. This figure has been modified from [ENREF 3 ENREF 3](#)<sup>3</sup>.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Estimated number of people with recent injecting drug use living with HCV viraemic infection, by country.

260x207mm (96 x 96 DPI)

ew




Figure 2. Proposed modified WHO Health Systems Framework for PWID.

306x171mm (96 x 96 DPI)

Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60